Building Blocks Catalog

300 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

1B novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

48B Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from March 2024

Recent News

  • 11 April 2024   Press Release

    Metrion Biosciences enhances High Throughput Screening services with access ...

    Cambridge, UK and Kyiv, Ukraine, 11 April 2024: Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries.

  • 27 March 2024   Press Release

    Enamine Announces Expansion of Its Library Synthesis Capabilities

    March, 2024, Kyiv, Ukraine. Enamine Ltd, the global leader in supplying small molecules and early drug discovery services, announces the expansion of its library synthesis capabilities with a focus on Enamine REAL compounds to further support the growing demands of agricultural and pharmaceutical companies, research institutes, and drug discovery centers.

  • 01 March 2024   News

    Enamine and Genez International Announce Strategic Collaboration to Launch ...

    We are excited to announce a strategic collaboration between Enamine, the world's leading provider of chemical building blocks, compound libraries, and biology services, and Genez International, a prominent enterprise with 15 years of experience in cross-border supply management, biopharmaceutical research and development, semiconductor equipment, and high-definition digital imaging systems.

"The α-amino acids, molecules of which have restricted conformational flexibility, are widely used in design of peptidomimetics, peptide models, and in systematic search for biologically active compounds. Among these amino acids, a distinct class of compounds can be highlighted, namely - conformationally rigid amino acids (CRA). Certain torsion angles, which describe the conformation of a polypeptide chain at the CRA, are "fixed" that allows predicting and controlling it to some extent. Many structural studies show that the CRA residues can dictate certain conformation of the peptide chain around them, consequently, they can stabilize or destabilize certain peptide secondary structure elements. Hence, the incorporation of the CRA in peptidomimetics and peptide models is a powerful tool for controlling their conformation and, to some extent, biological activity. In other words, CRA using as building blocks for peptidomimetic synthesis, gives better chances to find an efficient drug candidate."
Russ. Chem. Rev., 73 (2004), Nr 8, 785

We offer a set of conformationally rigid proline analogues. This amino acid is frequently found in peptide β-turns, which play an important role in peptide receptor recognition and antigen determination (J. Mol. Biol. 1988, 203, 221-232). It is highly probable that the bioisosteric replacement of proline analogues for proline in the known biologically active peptides/drugs may lead to new potential drug candidates.

The table below shows the structural formula of our conformationally rigid amino acids. All products are >96% chemically pure, and >90% optically pure (if applicable).

Type I: Unnatural α-amino acids

Type II: Unnatural β- and ω- amino acids

Successful examples of the peptidomimetic drug design using conformationally rigid a-amino acids (highlighted in red) are illustrated below:

Saxagliptin (Bristol-Myers Squibb and AstraZeneca)

Ximelagatran (AstraZeneca)
Nature Reviews/Drug Discovery, 3 (2004), 649

Prolylendopeptidase inhibitors
J. Med. Chem., 39, 2379 (1996)

Zabicipril
Tetrahedron Lett., 33, 7369 (1992)

FOLLOW US